We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer.
- Authors
Kim, Hongsik; Kim, Hana; Kim, Ryul; Jo, Hyunji; Kim, Hye Ryeon; Hong, Joohyun; Park, Joon Oh; Park, Young Suk; Kim, Seung Tae
- Abstract
Background : High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC). Methods : We analyzed 119 advanced BTC patients who received Gemcitabine/Cisplatin (GP) as a first-line treatment between November 2019 and April 2021. Next-generation sequencing (NGS), including TMB analysis, as a routine clinical practice was performed in 119 patients. The TruSightTM Oncology 500 assay from Illumina was used as a cancer panel. Results : Among 119 patients, 18 (18.5%) had a tumor with high TMB (≥ 10 Muts/Mb). There were no significant differences between the status of TMB and clinical outcomes with GP, including objective response rate (ORR) (P =.126), disease control rate (DCR) (p =.454), and median progression-free survival (PFS) (p =.599). The median overall survival (OS) was not different between patients with TMB-H and no TMB-H (p =.430). In subgroup analysis of 32 patients receiving immune checkpoint inhibitor (ICIs), there were significant differences in ORR (p =.034) and median PFS (p =.025) with ICIs between patients with and without TMB-H. Conclusions : This study revealed that TMB-H in advanced BTCs did not have a prognostic or role in the standard first-line treatment. However, TMB-H might be a predictive biomarker for response to ICIs in advanced BTC.
- Subjects
BILIARY tract cancer; OVERALL survival; PROGNOSIS; SURVIVAL rate; IMMUNE checkpoint inhibitors; PEMETREXED
- Publication
Technology in Cancer Research & Treatment, 2021, p1
- ISSN
1533-0346
- Publication type
Article
- DOI
10.1177/15330338211062324